Analysts Set Werewolf Therapeutics, Inc. (NASDAQ:HOWL) PT at $3.75

Shares of Werewolf Therapeutics, Inc. (NASDAQ:HOWL) have earned a consensus recommendation of “Hold” from the seven research firms that are presently covering the firm, Marketbeat reports. One analyst has rated the stock with a sell rating, four have issued a hold rating and two have issued a buy rating on the company. The average 1-year price objective among brokers that have issued ratings on the stock in the last year is $3.75.

HOWL has been the subject of a number of analyst reports. Wedbush lowered Werewolf Therapeutics from an “outperform” rating to a “neutral” rating and set a $1.00 price target for the company. in a research note on Friday, December 19th. Citizens Jmp lowered Werewolf Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Friday, December 19th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Werewolf Therapeutics in a research report on Wednesday, January 21st. HC Wainwright lowered their price target on Werewolf Therapeutics from $10.00 to $4.00 and set a “buy” rating on the stock in a report on Friday, December 19th. Finally, Citigroup downgraded Werewolf Therapeutics from a “market outperform” rating to a “market perform” rating in a research note on Friday, December 19th.

Insider Buying and Selling

In other Werewolf Therapeutics news, major shareholder Ansbert Gadicke sold 88,802 shares of the stock in a transaction dated Monday, November 24th. The shares were sold at an average price of $0.98, for a total transaction of $87,025.96. Following the completion of the transaction, the insider owned 5,168,303 shares of the company’s stock, valued at $5,064,936.94. This represents a 1.69% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, major shareholder Bioventures 2014 L.P. Mpm sold 88,802 shares of the firm’s stock in a transaction dated Monday, November 24th. The shares were sold at an average price of $0.98, for a total value of $87,025.96. Following the transaction, the insider owned 5,168,303 shares of the company’s stock, valued at approximately $5,064,936.94. The trade was a 1.69% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders sold 2,157,968 shares of company stock worth $1,830,115. 23.60% of the stock is owned by insiders.

Institutional Investors Weigh In On Werewolf Therapeutics

A number of hedge funds have recently made changes to their positions in HOWL. Jane Street Group LLC purchased a new position in Werewolf Therapeutics during the second quarter worth $409,000. Renaissance Technologies LLC lifted its holdings in shares of Werewolf Therapeutics by 48.6% in the 4th quarter. Renaissance Technologies LLC now owns 677,766 shares of the company’s stock worth $429,000 after acquiring an additional 221,766 shares during the last quarter. Citadel Advisors LLC purchased a new position in shares of Werewolf Therapeutics during the 3rd quarter worth about $304,000. Vanguard Group Inc. boosted its stake in shares of Werewolf Therapeutics by 8.5% during the 3rd quarter. Vanguard Group Inc. now owns 1,408,047 shares of the company’s stock worth $2,774,000 after purchasing an additional 109,796 shares during the period. Finally, Marshall Wace LLP bought a new position in Werewolf Therapeutics during the 2nd quarter valued at about $113,000. 64.84% of the stock is currently owned by hedge funds and other institutional investors.

Werewolf Therapeutics Stock Performance

Shares of NASDAQ HOWL opened at $0.72 on Tuesday. The stock has a market cap of $34.91 million, a PE ratio of -0.44 and a beta of 0.77. Werewolf Therapeutics has a 1 year low of $0.53 and a 1 year high of $2.38. The firm has a fifty day moving average price of $0.68 and a 200-day moving average price of $1.13. The company has a debt-to-equity ratio of 0.73, a current ratio of 3.87 and a quick ratio of 3.87.

About Werewolf Therapeutics

Werewolf Therapeutics, Inc (NASDAQ: HOWL) is a clinical-stage biotechnology company focused on the development of next-generation immunotherapies for the treatment of solid tumors. The company’s proprietary Conditional Activation Platform is designed to keep therapeutic molecules inert in healthy tissues and selectively activate them within the tumor microenvironment, aiming to enhance anti-tumor efficacy while minimizing systemic toxicity.

Leveraging this platform, Werewolf Therapeutics is advancing multiple programs that include conditionally activated cytokine candidates and bi-specific antibody constructs.